<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We performed a multivariable comparison of 125 consecutive patients with follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL) treated at our centers with either high-dose radioimmunotherapy (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>-RIT) using 131I-anti-CD20 (n = 27) or conventional high-dose therapy (C-HDT) (n = 98) and autologous hematopoietic stem cell transplantation </plain></SENT>
<SENT sid="1" pm="."><plain>The groups were similar, although more patients treated with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>-RIT had an elevated pretransplantation level of <z:chebi fb="4" ids="24996">lactate</z:chebi> dehydrogenase (41% versus 20%, P =.03) and elevated international prognostic score (41% versus 19%, P =.02) </plain></SENT>
<SENT sid="2" pm="."><plain>Patients treated with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>-RIT received individualized therapeutic doses of 131I-tositumomab (median, 19.7 GBq [531 mCi]) to deliver 17 to 31 Gy (median, 27 Gy) to critical organs </plain></SENT>
<SENT sid="3" pm="."><plain>Patients treated with C-HDT received total body irradiation plus chemotherapy (70%) or chemotherapy alone (30%) </plain></SENT>
<SENT sid="4" pm="."><plain>Patients treated with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>-RIT experienced improved overall survival (OS) (unadjusted hazard ratio [HR] for <z:hpo ids='HP_0011420'>death</z:hpo> = 0.4 [95% confidence interval (95% CI), 0.2-0.9], P =.02; adjusted HR, 0.3, P =.004) and progression-free survival (PFS) (unadjusted HR =.6 [95% C.I., 0.3-1.0], P =.06; adjusted HR, 0.5, P =.03) versus patients treated with C-HDT </plain></SENT>
<SENT sid="5" pm="."><plain>The estimated 5-year OS and PFS were 67% and 48%, respectively, for <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>-RIT and 53% and 29%, respectively, for C-HDT </plain></SENT>
<SENT sid="6" pm="."><plain>One hundred-day treatment-related mortality was 3.7% in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>-RIT group and 11% in the C-HDT group </plain></SENT>
<SENT sid="7" pm="."><plain>The probability of secondary <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo>/<z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>/<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) was estimated to be.076 at 8 years in the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>-RIT group and.086 at 7 years in the C-HDT group </plain></SENT>
<SENT sid="8" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>-RIT may improve outcomes versus C-HDT in patients with relapsed FL </plain></SENT>
</text></document>